NCT06802146 - Early Intervention in High Risk CCUS | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions

Clonal Cytopenia of Undetermined SignificanceCytopenia

Interventions

DRUG

Inqovi

Combination of a nucleoside metabolic inhibitor and cytidine deaminase inhibitor, 10mg DEC / 100mg CED tablet, taken orally per protocol.

Trial Locations (1)

RECRUITING

Dana-Farber Cancer Institute, Boston